GILD
Gilead Sciences, Inc.
Drug Manufacturers - General · Healthcare · United States
165.61
close · 2026-10-29
value
32
cheaper than peers32
quality
53
stronger fundamentals53
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 16.71× | 60 |
| EV to EBITDA | 14.98× | 52 |
| price to sales | 6.74× | 36 |
| price to book | 17.37× | 10 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 33.7% | 95 |
| return on equity | -20.7% | 56 |
| revenue growth | 10.2% | 53 |
| debt to equity | 223.5% | 10 |
4 of 4 measures available
Facts
| market cap | $205B |
| free cash flow | $9.77B |
| employees | 17,000 |
| first trade | 1992-01-22 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 6.78 | 0.38 | 4.50 | 3.64 |
| free cash flow | $9.46B | $10.30B | $7.42B | $8.34B |
| net income | $8.51B | $480.0M | $5.67B | $4.59B |
| revenue | $29.44B | $28.75B | $27.12B | $27.28B |
| unusual items | -$1.23B | -$9.21B | -$1.40B | -$4.30B |